Tonix Pharmaceuticals Holding Corp (TNXP.OB), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system or "CNS", said that it completed a pharmacokinetic or PK study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome or "FM".
The company noted that the study results support further development of TNX-102 as a product that can potentially deliver benefits similar to those observed in FM patients treated with very low dose cyclobenzaprine in the Company's dose-escalating Phase 2a study.
TONIX said that it is developing new formulations of cyclobenzaprine that are designed for bedtime use. The Company is investigating different technologies to improve the absorption of cyclobenzaprine. The technology applied in this study involves a mixture of cyclobenzaprine and lipids that the Company obtained from Lipocine, Inc. and is designated TNX-102 2.4 mg promicellar gelatin capsules, or gelcaps.
TONIX said that it is on track to initiate a pivotal efficacy study with the final formulation of TNX-102 in the first quarter of 2013.
| || |
| To receive FREE breaking news email alerts for Tonix Pharmaceuticals Holding Corp. and others in your portfolio|
by RTT Staff Writer
For comments and feedback: email@example.com